Minaris Regenerative Medicine is proud to share current and past news and announcements from its over twenty years of experience. Please see below for our press releases and announcements.

*This page may include mention of our past company names as it reflects content distributed in the past. The former companies Hitachi Chemical Advanced Therapeutics Solutions (HCATS, fomerly PCT or PCT Cell Therapy Services), apceth Biopharma GmbH, and Hitachi Chemical Co., Ltd. have been renamed Minaris Regenerative Medicine and are part of the Resonac Group.
December 10, 2023

Hiroto Bando Appointed CEO of Minaris Regenerative Medicine GmbH (Germany)

Munich, Germany - November 28th, 2023 - Minaris Regenerative Medicine GmbH, a leading contract development and manufacturing organization (CDMO) for the cell and gene therapy industry fully owned by Resonac Group, announces the appointment of Hiroto Bando, PhD as CEO of the European operations of Minaris Regenerative Medicine (Minaris) as of November 28, 2023. Hiroto Bando assumes this new role ...

September 6, 2023

Minaris Regenerative Medicine Selects’s Tempo Manufacturing Execution System to Scale Commercial Production

JERSEY CITY, N.J. - September 6th, 2023 -, leading technology provider for life sciences manufactures, announced that Minaris Regenerative Medicine, a leading contract development and manufacturing organization (CDMO) focused on cell and gene therapies, has selected Apprentice’s Tempo Manufacturing Execution System (MES) to digitize its commercial manufacturing in North America and ...

May 24, 2023

Minaris Regenerative Medicine Streamlining Contract Manufacturing with Veeva Vault Quality Suite Applications

Pleasanton, CA - May 24, 2023 - Veeva Systems (NYSE: VEEV) today announced that Minaris Regenerative Medicine, a leading contract development and manufacturing organization (CDMO) focused on cell and gene therapies, selected Veeva Vault QualityDocs and Veeva Vault Training to advance its global quality operations. Minaris Regenerative Medicine will use Veeva’s unified quality applications to ...

February 16, 2023

LIfT BioSciences and Minaris Regenerative Medicine Enter into a Development and Manufacturing Partnership for N-LIfT Allogeneic Neutrophil Based Cell Therapy

LONDON, UK and MUNICH, GERMANY - February 16, 2023 - LIfT BioSciences, a pioneering pre-clinical stage company moving into first-in-human trials with an allogeneic neutrophil progenitor based cell therapy, and Minaris Regenerative Medicine GmbH, a leading global contract development and manufacturing service provider for the cell and gene therapy industry, have entered into a development and ...

December 7, 2022

Minaris appoints Dr Helmut Lerch as Global Quality Head

MUNICH, GERMANY - December 7, 2022 - Minaris Regenerative Medicine is pleased to announce that, effective December 1, 2022, Helmut Lerch, PhD, who joined the company in July of this year as Head, Quality Management for Minaris Regenerative Medicine GmbH (the company’s Germany region) will assume the role of Global Quality Head, succeeding Jacqueline Veivia-Panter. Helmut is an accomplished ...

October 28, 2022

Minaris Regenerative Medicine GmbH and Mendus AB extend manufacturing partnership to large-scale production of DCP-001, an experimental allogeneic cell-based immunotherapy addressing tumor recurrence

Munich, Germany, and Stockholm, Sweden - Oct 28, 2022. Mendus AB (“Mendus publ; IMMU.ST), a biopharmaceutical company focused on immunotherapies addressing tumor recurrence and Minaris Regenerative Medicine GmbH („Minaris“), a leading contract development and manufacturing service provider for the cell and gene therapy industry, have extended their manufacturing partnership for technology ...

October 13, 2022

Showa Denko Materials and Kidswell Bio Enter Into an Agreement for Process Development and Clinical Manufacturing of Cell Therapy Products

Tokyo, Japan - October 13, 2022. Showa Denko Materials Co., Ltd. (Head office: Chiyoda-ku, Tokyo; President and CEO: Hidehito Takahashi; hereinafter “Showa Denko Materials”) and Kidswell Bio Corporation (Head office: Chuo-ku, Tokyo; President and CEO: Masaharu Tani; hereinafter “Kidswell Bio”) entered into an agreement to enable process development as well as clinical manufacturing...

October 12, 2022

Cellusion and Minaris Regenerative Medicine, a member of Showa Denko Materials, Enter into Business Alliance for the Manufacturing of CLS001 for a Corneal Endothelial Cell Regenerative Therapy

Allendale, NJ, USA and Yokohama, Japan - October 12, 2022 - Cellusion Inc. (CEO: Shin Hatou, M.D. Ph.D., “Cellusion”), a Japanese regenerative medicine startup aiming to solve the global corneal transplant waiting list problem with a unique differentiation induction method from iPS cells to Corneal Endothelial Cell Substitute from iPS Cells (CECSi Cells) for bullous keratopathy novel treatment...

June 27, 2022

Ixaka and Minaris Regenerative Medicine Sign Tech Transfer and GMP Manufacturing Agreement for Lead Cell Therapy Candidate REX-001

London, UK and Munich, Germany - June 27, 2022 - Ixaka Ltd Minaris Regenerative Medicine GmbH today announced that they have signed an agreement to enable technology transfer as well as clinical and commercial manufacture of REX-001.

All Posts